The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.
The World Health Assembly's new resolution on transparency in the market for health-related products is weaker than the original draft but still contains measures that could have a substantial impact on market access around the world, writes Neil Grubert.
A deep dive into the outlook and implications from the UK’s recently unveiled life sciences blueprint for a post-Brexit world.
Following the unveiling of the UK’s post-Brexit life sciences strategy, Neil Grubert looks at the measures related to market access, a particular challenge in the UK market and key to its future success in the sector.
Global market access analyst Neil Grubert discusses what are likely to be some of the key trends in market access this year and beyond, and the implications for the life sciences industry.